RELATION OF CA 15-3, CEA AND PSA TUMOR MARKERS IN PROSTATE CANCER PATIENTSAHMED MUTER SALIH, SALAM S. AL-AADHAMI AND HASSNA O. AL- JANABIAbstract Prostatic cancer with CA15-3 is a biochemical study and metabolic disturbances, this disease associated with a constant oxidative stress through reactive oxygen species (ROS) generation. The study designed to follow -up the level CA15-3 activity in prostatic cancer patients. A cross sectional study was carried out in Kirkuk city from May 2017 to March 2018. The number of prostatic cancer patients under study were 75 patients whose ages were between 40-85 years old. These patients admitted to Kirkuk oncology center. The control group included 90 unaffected male and their ages were between 40-85 years old. The distribution of prostatic tumor patients according to their ages showed that ages (71 to 75) years 12 %, ages (46 to 50) years 11%, ages and (61 to 65) years 10%. There is significant increase in serum caner Antigen 15-3 levels in serum of prostatic tumor patients before treatment (53.3) and after treatment (30.97). There is an increase in Carcinoembryonic Antigen levels in prostatic tumor patients before treatment (20.8 ng/mL) comparing with before treatment and the control The study showed that there is an increase in PSA levels in serum of prostatic tumor patients before treatment (88.0 ng/mL) and after treatment (45.0 ng/mL) compared with the control group. It was concluded that CA15-3, CEA and PSA level were increased significantly in prostatic cancer patients before treatment and slightly decreased after treatment.
Enter your contact information below to receive full paper.
|